Statistical Considerations for Clinical Trials During COVID-19: Steps for Mitigation
Abstract
To supplement both the FDA and EMA guidance, we describe six steps for mitigating impacts of COVID-19 for the sponsors who would like to maintain their trial integrity while protecting the safety of patients.
This paper has been withdrawn.
